Submitted by Anonymous (not verified) on 19 July 2024 - 11:56
Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Haematology-Hemostaseology;Uro-nephrology, PIP number: P/0128/2023
Source: